FDA approves deep brain stimulation device for neuro-related movement disorders
Click Here to Manage Email Alerts
The FDA has approved a battery-powered rechargeable deep brain stimulation system for patients with Parkinson’s disease and other disorders such as essential tremor, epilepsy and dystonia, according to the manufacturer.
In a company press release, Medtronic said the Percept RC Deep Brain Stimulation (DBS) system utilizes a surgically implanted device similar to a cardiac pacemaker and transmits electrical signals via slender wires to specific brain targets.
The Percept RC battery offers up to 15 years of service life, with patients experiencing recharging from 10% to 90% in less than an hour, per the release.
Nearly 70% of all DBS-eligible patients are estimated to require an MRI as part of their essential care, Medtronic said in the release, and the Percept system offers greater scan access for individuals with 3T scans and best-in-class 1.5T MRI scan labeling.
“Our DBS therapy with exclusive BrainSense technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments — something many of us unintentionally take for granted,” Amaza Reitmeier, vice president and general manager of brain modulation for Medtronic, said in the release. “We are transforming brain modulation through sensing-enabled DBS and will continue to drive therapy innovation, with the goal of many more peoples’ lives improved.”
The Medtronic Percept family also includes the Percept PC neurostimulator, BrainSense technology and SenSight directional leads, according to the release.